

REFERENCES / SUGGESTED READING – BONE TUMORS

1. Sarcomas I and II. *Hematol/Oncol Clin North Am* 9-10, June & August 1995, Patel SR, Benjamin RS ed.
2. Dahlin DC, Unni KK: Bone Tumors: *General Aspects and Data on 8,542 Cases*. Charles C Thomas, Springfield, IL, 1986.
3. Enneking WF, Spanier SS, Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. *Clin Orthop* 153:106, 1980.
4. Consensus Conference: Limb-sparing treatment of adult soft-tissue sarcomas and osteosarcomas. *JAMA* 254:1791, 1985.
5. Raymond AK, Chawla SP, Carrasco CH, et al: Osteosarcoma chemotherapy effect--a prognostic factor. *Semin Diagn Pathol*, 1987.
6. Link MP et al: The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. *N Engl J Med* 314: 1600-2, 1986.
7. Eilber F et al: Adjuvant chemotherapy for osteosarcoma: A randomized prospective trial. *J Clin Oncol* 5: 21-26, 1987.
8. Wilkins RM et al: Ewing's sarcoma of bone - experience with 140 patients. *Cancer* 58:2551-55, 1986.
9. Evans RG et al: Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: A report from the second intergroup study. *J Clin Oncol* 9:1173-80, 1991.
10. Multimodal therapy for the management of nonpelvic localized Ewing's sarcoma of bone: IECS II. *J Clin Oncol* 8:1514-24, 1990.
11. Cangir A et al: Ewing's sarcoma metastatic at diagnosis - Results and comparisons of two intergroup studies. *Cancer* 66:887-893, 1990.
12. Roth JA: Resection of pulmonary metastases from osteogenic sarcoma. *Cancer Bulletin*. 42:244-346, 1990.
13. Benjamin RS, Chu P, Patel SR, Raymond AK, Murray JA, Romsdahl MM, Ayala A: Dedifferentiated Chondrosarcoma - A treatable disease. *Proc Am Assoc Cancer Res* 36: 243, 1995 (abstr 1450)
14. Paulussen M et al. Localized Ewing' tumor of bone: Final results of the Cooperative Ewing's Sarcoma Study CESS 86. *J Clin Oncol* 19: 1818-29, 2001.

15. Ferrari S et al. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin and doxorubicin for patients with localized osteosarcoma of the extremity: a joint study by the Italian and Scandinavian Sarcoma Groups. *J Clin Oncol* 2005;23:8845, 8852.
16. Lewis IJ et al. Improvement in histologic response...EOI. *J Natl Can Inst* 2007;99:112-128
17. Bacci et al. Adjuvant and neo-adjuvant chemotherapy for osteosarcoma of the extremities: 27 yr experience at Rizzolli Institute, Italy. *Eur J Can* 2005;41:2836-45.
18. Granowetter L et al. Dose-intensified compared with standard chemotherapy... *J Clin Oncol* 2009; 27:2536-49.

REFERENCES / SUGGESTED READING-SOFT-TISSUE SARCOMAS

1. Sarcomas I and II. *Hematol/Oncol Clin North Am* 9-10, June&August 1995, Patel SR, Benjamin RS ed.
2. O'Bryan RM, et al: Dose response evaluation of adriamycin in human neoplasia. *Cancer* 39:1940-48, 1977.
3. Antman KH, et al: Response to Ifosfamide and Mesna: 124 previously treated patient with metastatic or unresectable sarcoma. *J Clin Oncol.* 7:126-131, 1989.
4. Bramwell VHC, et al: Cyclophosphamide versus Ifosfamide: preliminary report of a randomized phase II trial in adult soft tissue sarcomas. *Cancer Chemother Pharmacol.* 18:S13-S16, 1986.
5. Patel SR, et al: High-dose ifosfamide in bone and soft-tissue sarcomas: Results of phase 2 and pilot studies - Dose-response and schedule dependence. *J Clin Oncol* 15:2378-2384, 1997.
6. Edmonson JH, et al: Randomized comparison of Doxorubicin alone versus Ifosfamide plus Doxorubicin or Mitomycin, Doxorubicin and Cisplatin against advanced soft tissue sarcomas. *J Clin Oncol.* 11:1269-1275, 1993.
7. Antman K, et al: An intergroup phase III randomized study of Doxorubicin and Dacarbazine with or without Ifosfamide and Mesna in advanced soft tissue and bone sarcomas. *J Clin Oncol.* 11:1276-1285, 1993.

8. Santoro A, et al: Doxorubicin vs. CyVADIC vs Doxorubicin plus ifosfamide in first-line treatment of advanced soft-tissue sarcomas: A randomised study of the EORTC soft-tissue and bone sarcoma group. *J Clin Oncol*. 13:1537-45, 1995.

Sarcoma Meta-Analysis Collaboration: Adjuvant chemotherapy for localized resectable soft-tissue sarcoma of adults. *Lancet* 350:1647-54, 1997.

Patel SR et al: Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. *Am J Clin Oncol* 21(3): 317-21, 1998.

Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft-tissue sarcomas of the extremities and girdles: Results of the Italian Randomized cooperative group trial. *J Clin oncol* 19:1238-1247, 2001

Patel SR, Gandhi V, Jenkins J et al. Phase 2 clinical investigation of gemcitabine in advanced soft-tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. *J Clin Oncol* 19:3483-3489, 2001

Hensley, ML., Maki, R., Venkatraman, E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. *J Clin Oncol* 2002;**20**(12):2824-31.

Van Oosterom AT, Judson I, Verweij J et al. STI 571, an active drug in metastatic gastrointestinal stromal tumors, an EORTC phase 1 study. *Lancet* 358:1421, 2001

Verweij, J., Casali, P. G., Zalcberg, J., et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. *Lancet* 2004;**364**(9440):1127-34.

16. Demetri GD et al. Efficacy and safety of Sunitinib in patients with advanced GIST after failure of Imatinib: a randomized controlled trial. *Lancet* 368: 1329-1337, 2006

17. Blanke CD et al. Phase 3 randomized, intergroup trial assessing imatinib mesylate at 2 dose levels in patients with unresectable or metastatic GIST expressing the kit receptor tyrosine kinase:S0033. *J Clin Oncol* 2008. 26:626-32.

18. Blanke et al. Long term results from a randomized phase 2 trial of standard vs. higher dose imatinib for patients with unresectable or metastatic GIST expressing KIT. *J Clin Oncol* 2008. 26:620-25.

19. Pervaiz et al. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized respectable STS. *Cancer* 2008;113:573-81.

20. Patel SR, Zalberg J. Optimization of dose of Imatinib for the treatment of GIST – Lessons learned from the phase 3 trials. *Eur J Can* 44:501-509, 2008
21. DeMatteo RP et al. *Lancet* 373(9669), 1097-1104, 2009
22. Joensuu H et al. JAMA. 2012 Mar 28;307(12):1265-72.
23. Woll PJ, Reichardt P, Le Cesne A, et al. Adjuvant chemotherapy with doxorubicin, ifosfamide, and lenograstim for resected soft-tissue sarcoma (EORTC 62931): a multicentre randomised controlled trial. *The lancet oncology* 2012;13:1045-54.
24. Demetri GD et al. *Lancet* 2013; 381:295-302
25. van der Graaf WT et al. Pazopanib for met. STS (PALETTE): a randomized, double-blind, placebo controlled phase 3 trial. *Lancet* 379:1879-86, 2012
26. Demetri GD et al. Efficacy and safety of regorafenib for advanced GIST after failure of Imatinib and sunitinib (GRID): an international, multicenter, randomized, placebo-controlled phase 3 trial. *Lancet* 381:295-302, 2013
27. Judson I et al. Doxorubicin alone vs. intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic STS: a randomized controlled phase 3 trial. *Lancet Oncol* 15:415-23, 2014